1. Home
  2. JAGX vs CHRO Comparison

JAGX vs CHRO Comparison

Compare JAGX & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • CHRO
  • Stock Information
  • Founded
  • JAGX 2013
  • CHRO 2002
  • Country
  • JAGX United States
  • CHRO United States
  • Employees
  • JAGX N/A
  • CHRO N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • CHRO
  • Sector
  • JAGX Health Care
  • CHRO
  • Exchange
  • JAGX Nasdaq
  • CHRO Nasdaq
  • Market Cap
  • JAGX 12.9M
  • CHRO 11.3M
  • IPO Year
  • JAGX N/A
  • CHRO 2024
  • Fundamental
  • Price
  • JAGX $0.86
  • CHRO $1.68
  • Analyst Decision
  • JAGX
  • CHRO Strong Buy
  • Analyst Count
  • JAGX 0
  • CHRO 1
  • Target Price
  • JAGX N/A
  • CHRO N/A
  • AVG Volume (30 Days)
  • JAGX 311.0K
  • CHRO 104.9K
  • Earning Date
  • JAGX 03-31-2025
  • CHRO 03-04-2025
  • Dividend Yield
  • JAGX N/A
  • CHRO N/A
  • EPS Growth
  • JAGX N/A
  • CHRO N/A
  • EPS
  • JAGX N/A
  • CHRO N/A
  • Revenue
  • JAGX $10,480,000.00
  • CHRO N/A
  • Revenue This Year
  • JAGX $18.18
  • CHRO N/A
  • Revenue Next Year
  • JAGX $40.06
  • CHRO N/A
  • P/E Ratio
  • JAGX N/A
  • CHRO N/A
  • Revenue Growth
  • JAGX N/A
  • CHRO N/A
  • 52 Week Low
  • JAGX $0.78
  • CHRO $0.45
  • 52 Week High
  • JAGX $21.60
  • CHRO $4.84
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 45.91
  • CHRO 50.49
  • Support Level
  • JAGX $0.78
  • CHRO $1.59
  • Resistance Level
  • JAGX $1.03
  • CHRO $1.99
  • Average True Range (ATR)
  • JAGX 0.07
  • CHRO 0.29
  • MACD
  • JAGX 0.01
  • CHRO -0.06
  • Stochastic Oscillator
  • JAGX 30.44
  • CHRO 41.44

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About CHRO Chromocell Therapeutics Corporation

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Share on Social Networks: